- Home
- REFI vs JSPR Comparison
REFI vs JSPR Comparison
Compare REFI & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REFI | JSPR |
|---|---|---|
| Founded | 2021 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 278.8M | 26.3M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | REFI | JSPR |
|---|---|---|
| Price | $10.64 | $0.59 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | 157.5K | ★ 340.5K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | ★ 15.79% | N/A |
| EPS Growth | N/A | ★ 19.22 |
| EPS | ★ 0.57 | N/A |
| Revenue | ★ $48,857,628.00 | N/A |
| Revenue This Year | $17.47 | N/A |
| Revenue Next Year | $0.06 | N/A |
| P/E Ratio | $18.61 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.69 | $0.32 |
| 52 Week High | $13.49 | $2.69 |
Technical Indicators
Market Signals| Indicator | REFI | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 44.45 | 40.48 |
| Support Level | $9.69 | $0.56 |
| Resistance Level | $10.97 | $0.60 |
| Average True Range (ATR) | 0.21 | 0.06 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 0.00 | 21.00 |
Price Performance
Historical ComparisonAbout REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. The Company operates as one operating segment, and its primary investment objective is to provide attractive, risk-adjusted returns for stockholders over time, mainly through consistent current income (dividends and distributions) and secondarily, through capital appreciation. The company operates mainly within the USA itself.
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.